Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 OPB-111077 + bendamustine + rituximab in relapsed/refractory DLBCL
jRCT2080224718Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of OPB-111077 in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Primary safety and tolerability of OPB-111077 in combination with bendamustine and rituximab and Determination of recommended dose of OPB-111077. Started Jun 2019; status: completed.
02
Drugs
OPB-111077
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2080224718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224718.